Boston Scientific surges into 2026 with double-digit sales growth & record quarterly profit jump
Growth was broad-based across segments
Growth was broad-based across segments
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The transaction is anticipated to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated